Browse 313 head & neck cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Filter
1
Filter results
Results: 313
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
for
Head and Neck Squamous Cell Carcinoma,
Location: Nashville TN
Sponsor: Eben Rosenthal
Sex: All
Age: 19+
Code: NCT05747625
Phase1, Recruiting
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
for
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Location: Toronto
Sponsor: University Health Network, Toronto
Sex: All
Age: 18+
Code: NCT07408063
Phase2, Recruiting
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
for
Squamous Cell Carcinoma of Head and Neck,
Location: St Louis MO
Sponsor: Washington University School of Medicine
Sex: All
Age: 18+
Code: NCT07419464
Phase2, Recruiting
Window of Opportunity in Preserving Laryngeal Function Trial
for
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M),
Location: Pittsburgh PA
Sponsor: Matthew Spector
Sex: All
Age: 18+
Code: NCT07423078
Phase2, Recruiting
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Location: Willow Grove PA, Richmond VA, Fairfax VA, Rochester NY,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06769698
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
for
Squamous Cell Carcinoma of Head and Neck
Location: Boston MA, The Bronx NY, Philadelphia PA,
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Sex: All
Age: 18 - 70+
Code: NCT07219212
Phase1, Recruiting
A Study of the Use of 3D Technology to Guide Head and Neck Surgery
for
Surgery, Head and Neck Disorder
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 18+
Code: NCT06676592
Recruiting
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
for
Cranial Nerve Disorder, Head and Neck Carcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT04151082
Phase1, Phase2, Recruiting
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
for
Head and Neck Squamous Cell Carcinoma,
Location: New Haven CT
Sponsor: Yale University
Sex: All
Age: 18+
Code: NCT07172256
Phase2, Recruiting
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
for
Squamous Cell Carcinoma of Head and Neck
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center
Sex: All
Age: 18+
Code: NCT07455032
Phase1, Recruiting
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
for
Stage II Squamous Cell Carcinoma of the Head and Neck,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT06161545
Phase2, Recruiting
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
for
Cutaneous Squamous Cell Carcinoma of the Head and Neck,
Location: Sacramento CA
Sponsor: University of California, Davis
Sex: All
Age: 18+
Code: NCT06990737
Phase2, Recruiting
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT07465276
Phase2, Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
for
Metastatic Head-and-neck Squamous-cell Carcinoma,
Location: South Portland ME, Boston MA, New Haven CT,
Sponsor: AVEO Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06064877
Phase3, Recruiting
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors